Advanced in Teratocarcinosarcoma

Dr. Antonio Jimeno

Oncology
Office
1665 Aurora Ct Ste 3200, 
Aurora, CO 
Offers Telehealth
Advanced in Teratocarcinosarcoma
Office
1665 Aurora Ct Ste 3200, 
Aurora, CO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Antonio Jimeno is an Oncologist in Aurora, Colorado. Dr. Jimeno is rated as an Advanced provider by MediFind in the treatment of Teratocarcinosarcoma. His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Glioma, Laryngeal Cancer, and Thyroid Cancer.

His clinical research consists of co-authoring 169 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in CO
Hospital Affiliations
University Of Colorado Hospital Authority
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SelectHealth
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Office
1665 Aurora Ct Ste 3200, Aurora, CO 80045
Other Locations
University of Colorado Hospital
1665 Aurora Ct Fl 2, Aurora, CO 80045

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase II Study of Enzalutamide (NSC# 766085) for Patients With Androgen Receptor Positive Salivary Cancers
A Phase II Study of Enzalutamide (NSC# 766085) for Patients With Androgen Receptor Positive Salivary Cancers
Enrollment Status: Active_not_recruiting
Publish Date: February 11, 2026
Intervention Type: Drug
Study Drug: Enzalutamide
Study Phase: Phase 2
Phase I/II Trial of Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV-unrelated Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Phase I/II Trial of Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV-unrelated Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Enrollment Status: Completed
Publish Date: February 03, 2025
Intervention Type: Drug, Radiation
Study Drug: Atezolizumab
Study Phase: Phase 1
A First-in-Human, Two-Part, Open-Label, Phase I/II Study of DSP107 in Subjects with Advanced Solid Tumors Including a Dose-escalation Safety Study (part 1) and Preliminary Efficacy Assessment of DSP107 As Monotherapy and in Combination with Atezolizumab (part 2)
A First-in-Human, Two-Part, Open-Label, Phase I/II Study of DSP107 in Subjects with Advanced Solid Tumors Including a Dose-escalation Safety Study (part 1) and Preliminary Efficacy Assessment of DSP107 As Monotherapy and in Combination with Atezolizumab (part 2)
Enrollment Status: Active_not_recruiting
Publish Date: January 09, 2025
Intervention Type: Biological
Study Drugs: DSP107, Atezolizumab
Study Phase: Phase 1/Phase 2
A Phase 1/2, First-in-Human, Multicenter, Open-Label Study of SQZ-eAPC-HPV as Monotherapy and in Combination With Immune Checkpoint Inhibitor(s) in Patients With HPV16+ Recurrent, Locally Advanced, or Metastatic Solid Tumors
A Phase 1/2, First-in-Human, Multicenter, Open-Label Study of SQZ-eAPC-HPV as Monotherapy and in Combination With Immune Checkpoint Inhibitor(s) in Patients With HPV16+ Recurrent, Locally Advanced, or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: February 23, 2024
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab or Other Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab or Other Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug, Biological
Study Drugs: SQZ-PBMC-HPV, Atezolizumab, Ipilimumab, Nivolumab
Study Phase: Phase 1
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies
Enrollment Status: Completed
Publish Date: February 22, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Dose Escalation and Expansion Study of OMP-305B83 in Subjects With Solid Tumors
A Phase 1 Dose Escalation and Expansion Study of OMP-305B83 in Subjects With Solid Tumors
Enrollment Status: Completed
Publish Date: August 11, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: December 09, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 8 Less Clinical Trials

169 Total Publications

Improved Methods for the Stable Generation of Human Papillomavirus-Driven Head and Neck Cancer Cell Lines.
Improved Methods for the Stable Generation of Human Papillomavirus-Driven Head and Neck Cancer Cell Lines.
Journal: Molecular carcinogenesis
Published: July 07, 2025
Similar Doctors
Advanced in Teratocarcinosarcoma
Dr. Theresa Medina
Hematology | Oncology
Advanced in Teratocarcinosarcoma
Dr. Theresa Medina
Hematology | Oncology

University Physicians Incorporated

13123 E 16th Ave, 
Aurora, CO 
 (0.4 miles away)
720-777-1234
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Theresa Medina is a Hematologist and an Oncologist in Aurora, Colorado. Dr. Medina is rated as a Distinguished provider by MediFind in the treatment of Teratocarcinosarcoma. Her top areas of expertise are Melanoma, Merkel Cell Carcinoma, Melanoma of the Eye, and Metastatic Uveal Melanoma.

Experienced in Teratocarcinosarcoma
Dr. Karl Lewis
Hematology | Oncology
Experienced in Teratocarcinosarcoma
Dr. Karl Lewis
Hematology | Oncology
12605 E 16th Ave, 
Aurora, CO 
 (0.1 miles away)
720-848-0000
Languages Spoken:
English
See accepted insurances

Karl Lewis is a Hematologist and an Oncologist in Aurora, Colorado. Dr. Lewis is rated as a Distinguished provider by MediFind in the treatment of Teratocarcinosarcoma. His top areas of expertise are Melanoma, Basal Cell Skin Cancer, Merkel Cell Carcinoma, and Neuroendocrine Tumor.

Experienced in Teratocarcinosarcoma
Dr. Sapna Patel
Hematology | Oncology
Experienced in Teratocarcinosarcoma
Dr. Sapna Patel
Hematology | Oncology

University Physicians Incorporated

12605 E 16th Ave, Uchealth Anschutz Medical, 
Aurora, CO 
 (0.1 miles away)
720-848-0000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sapna Patel is a Hematologist and an Oncologist in Aurora, Colorado. Dr. Patel is rated as an Advanced provider by MediFind in the treatment of Teratocarcinosarcoma. Her top areas of expertise are Melanoma of the Eye, Melanoma, Metastatic Uveal Melanoma, and Primitive Neuroectodermal Tumor (PNET).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jimeno's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 24 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile